Multicenter study of the performance of NTM Elite agar for the detection of nontuberculous mycobacteria from patients with cystic fibrosis

被引:1
作者
Andre, Emmanuel [1 ,2 ]
Lorent, Natalie [3 ]
Beuselinck, Kurt [1 ]
Deiwick, Susanne [4 ]
Dupont, Lieven [3 ]
Gafsi, Johanne [5 ]
Laenen, Lies [1 ,2 ]
Raymaekers, Lise [1 ]
Van Bleyenbergh, Pascal [3 ]
Perry, John D. [6 ]
Kahl, Barbara C. [4 ]
机构
[1] UZ Leuven Univ Hosp, Lab Med Dept, Leuven, Belgium
[2] Katholieke Univ Leuven, Dept Microbiol Immunol & Transplantat, Lab Clin Microbiol, Leuven, Belgium
[3] Univ Hosp Leuven, Resp Dis Dept, Leuven, Belgium
[4] Univ Hosp Munster, Inst Med Microbiol, Munster, Germany
[5] BioMerieux Global Clin Affairs, Marcy Letoile, France
[6] Freeman Rd Hosp, Microbiol Dept, Newcastle Upon Tyne, England
来源
MICROBIOLOGY SPECTRUM | 2024年 / 12卷 / 10期
关键词
nontuberculous mycobacteria; cystic fibrosis; mycobacterial culture; RAPIDLY-GROWING MYCOBACTERIA; PULMONARY-DISEASE; PREVALENCE;
D O I
10.1128/spectrum.02736-23
中图分类号
Q93 [微生物学];
学科分类号
071005 ; 100705 ;
摘要
The performance of a novel selective agar was evaluated against the performance of conventional mycobacterial cultures, i.e., a combination of the mycobacterial growth indicator tube (MGIT) with L & ouml;wenstein-Jensen (LJ), for the detection of nontuberculous mycobacteria (NTM) in sputum samples from people with cystic fibrosis (pwCF). Two hundred eighty-three sputum samples (231 fresh sputum and 52 spiked sputum) from 143 pwCF were collected. They were inoculated without prior decontamination on NTM Elite agar (30 degrees C +/- 2 degrees C for 28 days) and inoculated on both MGIT and LJ (35 degrees C-37 degrees C for 6-8 weeks) after N-acetyl-L-cysteine-2% sodium hydroxide decontamination. NTM were identified by Matrix-Assisted Laser Desorption Ionization/Time of Flight Mass Spectrometry and/or PCR, and whole-genome sequencing. A total of 67 NTM were recovered overall by the combination of all culture media. NTM Elite agar allowed the recovery of 65 NTM (97%), compared to 22 for the conventional MGIT and LJ media combination (32.8%), including 22 NTM for MGIT (32.8%) and 3 NTM with the LJ medium (4.5%). For Mycobacterium abscessus complex, the sensitivity of NTM Elite agar was 95% compared with a sensitivity of 30% for the conventional MGIT and LJ media combination. Overall, 17.3% of cultures on NTM Elite agar were contaminated with other micro-organisms vs 46.3% on MGIT and 77% on LJ. This study shows that the novel selective agar (NTM Elite agar) significantly outperforms the conventional MGIT and LJ media combination in terms of sensitivity, selectivity, and ease of culture, without the requirement of an L3 laboratory.IMPORTANCENontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. Mycobacterium avium complex and Mycobacterium abscessus complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium. Nontuberculous mycobacteria (NTM) are significant pulmonary pathogens in patients with pre-existing structural lung conditions such as cystic fibrosis, bronchiectasis, or chronic obstructive pulmonary disease. Mycobacterium avium complex and Mycobacterium abscessus complex (MABSC) are the most frequently isolated organisms. Compared to the recommended culture method for NTM, which combines solid and liquid culture media, NTM Elite agar enables a faster/easier diagnosis and speeds up identification and susceptibility testing as the final reading is at 28 days instead of 6-8 weeks for the conventional mycobacterial cultures. In addition, for the NTM Elite agar, no decontamination stage before inoculation is necessary, unlike the conventional mycobacterial cultures. NTM Elite agar is derived from a formulation of medium adapted to rapidly growing mycobacteria (RGM). The medium enables the growth of RGM while suppressing other flora. It is supported with published clinical data showing the benefits of this medium.
引用
收藏
页数:11
相关论文
共 50 条
  • [41] A novel culture medium for isolation of rapidly-growing mycobacteria from the sputum of patients with cystic fibrosis
    Preece, Clair L.
    Perry, Audrey
    Gray, Bethany
    Kenna, Dervla T.
    Jones, Amanda L.
    Cummings, Stephen P.
    Robb, Ali
    Thomas, Matthew F.
    Brodlie, Malcolm
    O'Brien, Christopher J.
    Bourke, Stephen J.
    Perry, John D.
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (02) : 186 - 191
  • [42] Detection of mycobacterial DNA from sputum of patients with cystic fibrosis
    M Devine
    JE Moore
    J Xu
    BC Millar
    K Dunbar
    T Stanley
    PG Murphy
    AOB Redmond
    JS Elborn
    [J]. Irish Journal of Medical Science, 2004, 173 : 96 - 98
  • [43] In vitro stimulation with nontuberculous mycobacteria induced a stronger cytokine response in leukocytes isolated from individuals with latent tuberculosis compared to those isolated from active tuberculosis or cystic fibrosis patients
    Rabe, Hardis
    Lonnermark, Elisabeth
    Johansson, Ewa
    Gilljam, Marita
    Jonsson, Bodil
    [J]. TUBERCULOSIS, 2024, 147
  • [44] Current Opinions in the Treatment of Pulmonary Nontuberculous Mycobacteria in Non-Cystic Fibrosis Patients: Mycobacterium abscessus Group, Mycobacterium avium Complex, and Mycobacterium kansasii
    Barbara A. Brown-Elliott
    Julie V. Philley
    Jeana L. Benwill
    Richard J. Wallace
    [J]. Current Treatment Options in Infectious Diseases, 2014, 6 (4) : 392 - 408
  • [45] Evaluation of CHROMagar™ B. cepacia agar for the detection of Burkholderia cepacia complex species from sputum samples of patients with cystic fibrosis
    Maruri-Aransolo, Ainhize
    Caballero, Juan de Dios
    Michelena, Malkoa
    Medina-Pascual, Maria Jose
    Carrasco, Gema
    Asensio, Oscar
    Cols, Maria
    Canton, Rafael
    [J]. EUROPEAN JOURNAL OF CLINICAL MICROBIOLOGY & INFECTIOUS DISEASES, 2024, 43 (07) : 1349 - 1353
  • [46] Bronchopulmonary infection-colonization patterns in Spanish cystic fibrosis patients: Results from a national multicenter study
    de Dios Caballero, Juan
    del Campo, Rosa
    Royuela, Ana
    Sole, Amparo
    Maiz, Luis
    Olveira, Casilda
    Quintana-Gallego, Esther
    de Gracia, Javier
    Cobo, Marta
    de la Pedrosa, Elia Gomez G.
    Oliver, Antonio
    Canton, Rafael
    Sole, Amparo
    Cortell, Isidoro
    Asensio, Oscar
    Garcia, Gloria
    Teresa Martinez, Maria
    Cols, Maria
    Salcedo, Antonio
    Vazquez, Carlos
    Baranda, Felix
    Giron, Rosa
    Quintana, Esther
    Delgado, Isabel
    Angeles de Miguel, Maria
    Garcia, Marta
    Oliva, Concepcion
    Concepcion Prados, Maria
    Isabel Barrio, Maria
    Dolores Pastor, Maria
    Olveira, Casilda
    de Gracia, Javier
    Alvarez, Antonio
    Escribano, Amparo
    Castillo, Silvia
    Figuerola, Joan
    Togores, Bernat
    Oliver, Antonio
    Lopez, Carla
    de Dios Caballero, Juan
    Tato, Marta
    Maiz, Luis
    Suarez, Lucrecia
    Canton, Rafael
    [J]. JOURNAL OF CYSTIC FIBROSIS, 2016, 15 (03) : 357 - 365
  • [47] Distribution of OGTT-Related Variables in Patients with Cystic Fibrosis from Puberty to Adulthood: An Italian Multicenter Study
    Foppiani, Andrea
    Ciciriello, Fabiana
    Bisogno, Arianna
    Bricchi, Silvia
    Colombo, Carla
    Alghisi, Federico
    Lucidi, Vincenzina
    Catena, Maria Ausilia
    Lucanto, Mariacristina
    Mari, Andrea
    Bedogni, Giorgio
    Battezzati, Alberto
    [J]. JOURNAL OF PERSONALIZED MEDICINE, 2023, 13 (03):
  • [48] Prospective Multicenter Study of Pneumocystis jirovecii Colonization among Cystic Fibrosis Patients in France
    Hernandez-Hernandez, Francisca
    Frealle, Emilie
    Caneiro, Patrick
    Salleron, Julia
    Durand-Joly, Isabelle
    Accoceberry, Isabelle
    Bouchara, Jean-Philippe
    Wallaert, Benoit
    Dei-Cas, Eduardo
    Delhaes, Laurence
    [J]. JOURNAL OF CLINICAL MICROBIOLOGY, 2012, 50 (12) : 4107 - 4110
  • [49] Toward the Standardization of Mycological Examination of Sputum Samples in Cystic Fibrosis: Results from a French Multicenter Prospective Study
    Coron, Noemie
    Pihet, Marc
    Frealle, Emilie
    Lemeille, Yolande
    Pinel, Claudine
    Pelloux, Herve
    Gargala, Gilles
    Favennec, Loic
    Accoceberry, Isabelle
    Durand-Joly, Isabelle
    Dalle, Frederic
    Huet, Frederic
    Fanton, Annlyse
    Boldron, Amale
    Loeuille, Guy-Andre
    Domblides, Philippe
    Coltey, Berengere
    Pin, Isabelle
    Llerena, Catherine
    Troussier, Francoise
    Person, Christine
    Marguet, Christophe
    Wizla, Nathalie
    Thumerelle, Caroline
    Turck, Dominique
    Bui, Stephanie
    Fayon, Michael
    Duhamel, Alain
    Prevotat, Anne
    Wallaert, Benoit
    Leroy, Sylvie
    Bouchara, Jean-Philippe
    Delhaes, Laurence
    [J]. MYCOPATHOLOGIA, 2018, 183 (01) : 101 - 117
  • [50] Detection of pathogenic bacteria and biomarkers in lung specimens from cystic fibrosis patients
    Tolle, James J.
    Jadhao, Samadhan
    Patel, Brijesh
    Sun, Heying
    Eastman, Susan
    Hartert, Tina
    Ku, David N.
    Anderson, Larry J.
    [J]. JOURNAL OF BREATH RESEARCH, 2024, 18 (04)